- Pharma/Biotech (20)
- Intellectual Property (9)
- Information Technology (5)
- Company/Commercial (4)
- Regulatory and compliance (4)
- Media/Entertainment/Sport (3)
- Banking / Finance (2)
- Corporate (2)
- Employment (2)
- Funds (2)
- Litigation / Dispute Resolution (2)
- Telecoms (2)
- Construction (1)
- Energy (1)
- Insurance/reinsurance (1)
- Pensions (1)
- Planning (1)
- Public Sector Watch (1)
- Real Estate (1)
- Tax (1)
- Transport (Including aviation and shipping) (1)
Sort By: Newest first | Oldest first
A decision by the German Federal Court of Justice has confirmed the broad interpretation of the term ‘health claim’ in the context of Regulation (EC) No 1924/2006.
The European Medicines Agency launched a new post-marketing surveillance system in the autumn called the ‘Black Triangle’ scheme.
The MHRA offers useful guidance on the difference between apps that are regulated as medical devices and those that are related to healthcare but do not qualify.
In the UAE, there are two separate jurisdictions that need to be considered. This update will focus on some recent developments in both jurisdictions.
A number of life sciences industry bodies have jointly published a report entitled ‘From vision to action: delivery of the strategy for UK life sciences’.
Taylor Wessing has launched its third Cambridge newsletter, providing legal news and updates for companies in Cambridge and the surrounding areas.
Appointment as a trust special administrator to an NHS trust does not give rise to a power to take any action or make any recommendations in relation to any other NHS trust.
Pharmaceutical benefit assessments play an increasingly important role in refunds by the national health services.
The Advocate General’s opinion in Georgetown University has been released. It fails to recommend whether or not more than one SPC can be granted based on the same patent.
The Deputy Pensions Ombudsman gives an indication of circumstances in which decision makers should give detailed reasons for their decisions.
The provisions proposed by the European Commission in its regulation target better supervision of the accreditation bodies.
Medicinal products may be protected by a paediatric extension, which extends the lifetime of a supplementary protection certificate by a further six months.
The number of candidates entering and progressing through the product pipelines of some leading originator pharmaceutical companies has diminished.
Taylor Wessing has announced the hire of Matthew Jones to its construction and engineering group.
The CJEU has given judgment in case C-109/12, which concerns some practical effects of the borderline between medicinal products and medical devices.
ENVI has voted to approve a suite of amendments to the draft European legislation governing medical devices.
Investigations have recently been reported into allegations that millions of pounds worth of bribes have been paid to boost drug sales in China.
The Court of Appeal has today handed down an important decision that concerns a patent for a synthetic copolymer known as copolymer-1.
The regulation of similar biological medicinal products (‘biosimilars’) is governed by article 10(4) of Directive 2001/83 as amended, supplemented by the annex to the directive.
Patent infringement by pre-expiry offer to supply a product after the patent has expired is an area of acute difficulty in Austria.